49,088 results match your criteria Hodgkin Disease

Revising the Treatment Pathways in Lymphoma: New Standards of Care-How Do We Choose?

Am Soc Clin Oncol Educ Book 2022 Apr;42:1-14

BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada.

Diffuse large B-cell lymphoma and follicular lymphoma are the most commonly encountered non-Hodgkin lymphomas in clinical practice. Both are biologically heterogeneous, with management strategies that are becoming increasingly complex. Diffuse large B-cell lymphoma typically exhibits aggressive behavior but can be cured in the majority of cases with immunochemotherapy. Read More

View Article and Full-Text PDF

Deficiency of Human Adenosine Deaminase Type 2 - A Diagnostic Conundrum for the Hematologist.

Front Immunol 2022 3;13:869570. Epub 2022 May 3.

Pediatric Allergy Immunology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Deficiency of adenosine deaminase type 2 (DADA2) was first described in 2014 as a monogenic cause of polyartertitis nodosa (PAN), early onset lacunar stroke and livedo reticularis. The clinical phenotype of DADA2 is, however, very broad and may involve several organ systems. Apart from vasculitis, children may present with i) Hematological manifestations (ii) Lymphoproliferation and iii) Immunodeficiencies. Read More

View Article and Full-Text PDF

In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection.

Med (N Y) 2021 Oct;2(10):1171-1193.e11

Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Köln, Germany; Cancer Center Cologne Essen - Partner Site Cologne, CIO Cologne, University of Cologne, Köln, Germany; German Hodgkin Study Group, Cologne, Germany. Electronic address:

Background: Individualization of treatment in Hodgkin's lymphoma is necessary to improve cure rates and reduce treatment side effects. Currently, it is hindered by a lack of genomic characterization and sensitive molecular response assessment. Sequencing of cell-free DNA is a powerful strategy to understand the cancer genome and can be used for extremely sensitive disease monitoring. Read More

View Article and Full-Text PDF
October 2021

Cell-free DNA in Hodgkin Lymphoma: A future standard?

Med (N Y) 2021 Oct;2(10):1117-1119

Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address:

In this issue of Med, Sobesky et al. investigate the translational utility of sequencing cell-free DNA to describe genetic features of classic Hodgkin Lymphoma (HL) and to evaluate minimal residual disease (MRD) for patients treated in a clinical trial. Read More

View Article and Full-Text PDF
October 2021

Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trial.

J Immunother Cancer 2022 May;10(5)

Pediatrics, New York Medical College, Valhalla, New York, USA

Background: Cure rates for Hodgkin's lymphoma are excellent, but excess short-term and long-term morbidities from treatment remain a concern. Immunotherapy targeting both tumor antigens and the immunosuppressive tumor microenvironment in children, adolescents, and young adults with Hodgkin's lymphoma may improve early response rates and eliminate toxic chemotherapy and radiation, thus minimizing toxicity. We conducted a phase II study to evaluate the safety and overall response rate of brentuximab vedotin and rituximab in combination with risk-adapted chemotherapy in children, adolescents, and young adults with newly diagnosed classic Hodgkin's lymphoma (cHL). Read More

View Article and Full-Text PDF

Radiation-induced coronary artery disease: a difficult clinical conundrum.

Clin Med (Lond) 2022 May;22(3):251-256

Royal Free Hospital, London, UK.

Accelerated coronary artery disease seen following radiation exposure is termed 'radiation-induced coronary artery disease' (RICAD) and results from both the direct and indirect effects of radiation exposure. Long-term data are available from survivors of nuclear explosions and accidents, nuclear workers as well as from radiotherapy patients. The last group is, by far, the biggest cause of RICAD presentation. Read More

View Article and Full-Text PDF

Hematopoietic Stem-Cell Transplant Utilization in Relapsed/Refractory Hodgkin Lymphoma: A Population-Level Analysis of Statewide Claims Data.

JCO Clin Cancer Inform 2022 May;6:e2100135

Division of Hematology/Oncology, Tufts Medical Center, Boston, MA.

Purpose: Although hematologic malignancies affect adults of all ages, few data exist on the real-world patterns of care for patients younger than 65 years in the United States. Understanding patterns of care from diagnosis through relapsed disease may provide insight about care across community and academic centers. We used a large statewide claims database to describe the path of Hodgkin lymphoma (HL) treatment among adults age < 65 years at diagnosis. Read More

View Article and Full-Text PDF

Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies.

Blanca Scheijen

Cancer Drug Resist 2019 19;2(3):647-664. Epub 2019 Sep 19.

Department of Pathology, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, GA 6525, Nijmegen, the Netherlands.

Despite the introduction of many novel therapies into the clinic to target hematological malignancies, glucocorticoids (GCs) still remain one of the cornerstone drugs in first-line treatment of lymphoid tumors. However, a significant portion of the patients display acquired GC therapy resistance. This review will describe the different molecular mechanisms that contribute to GC resistance in lymphoid tumors. Read More

View Article and Full-Text PDF
September 2019

Tamponade with recurrent chylopericardium in patient with non-Hodgkin's lymphoma: chemotherapy is the key management after pericardiocentesis.

BMJ Case Rep 2022 May 17;15(5). Epub 2022 May 17.

Department of Cardiology and Vascular Medicine, Universitas Airlangga Hospital, Surabaya, East Java, Indonesia.

Cardiac tamponade, the accumulation of fluid in the pericardial space, leads to impaired venous return, loss of left ventricular preload and haemodynamic collapse. Chylopericardium is an unusual cause of the pericardial effusion. This is often secondary to malignancy. Read More

View Article and Full-Text PDF

Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again.

Am Soc Clin Oncol Educ Book 2022 Apr;42:1-14

Division of Hematology, Oncology, and Stem Cell Transplant, Department of Pediatrics, Stanford University, Stanford, CA.

The role of immune checkpoint inhibitors (ICIs) in the treatment of pediatric cancers continues to evolve. Such therapies function by augmenting existing antitumor T-cell responses that have been rendered ineffective by inhibitory pathways. Although ICIs have proven highly effective for adult cancers, initial phase I/II clinical trials using single-agent ICIs against unselected pediatric cancers have been overall disappointing. Read More

View Article and Full-Text PDF


Blood 2022 May 17. Epub 2022 May 17.

Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Research Hospital - IRCCS, Milano,, Italy.

Diffuse large B-cell lymphoma (DLBCL) is a heterogenous subtype of non-Hodgkin lymphoma. Relapsed/refractory disease represents remains an unmet medical need, despite the introduction of novel cellular and targeted therapies. Loncastuximab tesirine is a CD19-targeting antibody-drug conjugate approved by the US Food and Drug Administration for relapsed DLBCL after two lines of systemic therapy based on a trial showing a 48. Read More

View Article and Full-Text PDF

CAR T-cell therapy for relapsed/refractory non-Hodgkin's lymphoma: a comprehensive review.

Clin Adv Hematol Oncol 2022 May;20(5):309-318

Department of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago, Illinois.

Non-Hodgkin lymphoma (NHL) is the seventh most common type of malignancy worldwide, with approximately 544,000 cases diagnosed in 2020.[1-3] The vast majority of NHLs are derived from B cells. The more than 80 subtypes of B-cell NHL are categorized according to their typical clinical course: indolent or aggressive. Read More

View Article and Full-Text PDF

Changing causes of death in persons with haematological cancers 1975-2016.

Leukemia 2022 May 16. Epub 2022 May 16.

State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong Province, China.

Causes of death in persons with haematological cancers include the index cancer, a new cancer or a seemingly unrelated cause such as cardio-vascular disease. These causes are complex and sometimes confounded. We analyzed trends in cause of death in 683,333 persons with an index haematological cancer diagnosed in 1975-2016 reported in the Surveillance, Epidemiology and End Results dataset. Read More

View Article and Full-Text PDF

Frequency, Distribution Of Subtypes And Immunohistochemical Profile Of Non-Hodgkin Lymphoma In Paediatric And Adolescent Patients.

J Ayub Med Coll Abbottabad 2022 Apr-Jun;34(2):351-356


Background: Non-Hodgkin lymphoma is a common malignant disorder in paediatric and adolescent age group. There is a need of large-scale studies to understand the disease pattern in Pakistan as no official registry exist in most of the developing countries. This study comprised a large cohort of 223 patients, spanned over a decade from January 2008-December 2019 and aimed to report the prevalence of subtypes, demographics and immunohistochemical profile from this region. Read More

View Article and Full-Text PDF

Current Treatment of Peripheral T-cell Lymphoma.

Oncology (Williston Park) 2022 May;36(5):293-305

The peripheral T-cell lymphomas (PTCLs) are a notoriously diverse family of non-Hodgkin lymphomas with generally aggressive biology. Clinical management is challenging given a largely inadequate literature base comprised of few randomized trials and heterogeneous observational reports. Herein, we provide an account of our practice in the treatment of the 3 most common nodal PTCLs: PTCL, not otherwise specified, angioimmunoblastic T-cell lymphoma, and anaplastic large cell lymphoma (ALCL). Read More

View Article and Full-Text PDF

Nodular Lymphocyte-predominant Hodgkin Lymphoma With Nodular Sclerosis: An Underrecognized Feature Associated With Pattern D.

Am J Surg Pathol 2022 May 16. Epub 2022 May 16.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with unusual features, including some that can overlap morphologically with classic Hodgkin lymphoma (CHL), have been described. Herein, we describe 12 cases of NLPHL with fibrous bands and capsular fibrosis resembling, in part, nodular sclerosis (NS) CHL. Seven of 12 cases harbored Reed-Sternberg-like cells, further suggestive of CHL, but all cases lacked associated eosinophils and/or plasma cells in the background. Read More

View Article and Full-Text PDF

COVID-19-Associated Pneumonia in a B-Cell-Depleted Patient With Non-Hodgkin Lymphoma: Recovery With Hyperimmune Plasma.

J Hematol 2022 Apr 22;11(2):77-80. Epub 2022 Apr 22.

Internal Medicine Unit, Legnano Hospital, ASST Ovest Milanese, Legnano (MI), Italy.

Coronavirus disease 2019 (COVID-19) can have a severe course in immunocompromised hosts and patients with hematological malignancies. In some cases, the bad prognosis is associated with the lack of B lymphocytes, with impaired antibody production and inefficient viral clearance. We report a case of a 67-year-old woman with a story of non-Hodgkin lymphoma treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), who got a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection while being totally depleted of B cells. Read More

View Article and Full-Text PDF

Aberrant HSP90 Expression in Lymphocytes and HSP90 Response to Anti-PD-1 Therapy in Lymphoma Patients.

Front Immunol 2022 28;13:893137. Epub 2022 Apr 28.

Department of Immunology, Lomonosov Moscow State University, Moscow, Russia.

HSP90 family of molecular chaperones has been shown to be implicated in various stages of tumor growth and development. Recent studies have highlighted the role of extracellular HSP90 in tumor immunology, however, the role that HSP90 plays in the regulation of immune responses and the impact of cancer immunotherapy, including immune checkpoint blockade, on HSP90 is still unclear. Here we assessed the surface and intracellular expression of constitutive cytosolic HSP90β isoform, mitochondrial HSP90 homolog TRAP1 and co-chaperone STIP1/HOP in T, NK, B and NKT cells derived from peripheral blood and bone marrow samples of patients with Hodgkin and B-cell Non-Hodgkin lymphomas. Read More

View Article and Full-Text PDF

Case Report: Development of Diffuse Large B Cell Lymphoma a Long Time After Hairy Cell Leukemia.

Pathol Oncol Res 2022 29;28:1610338. Epub 2022 Apr 29.

Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.

Hairy cell leukaemia (HCL) is a rare B cell malignancy with an indolent course leading to pancytopaenia due to bone marrow infiltration. It has been proposed that HCL patients are at risk of developing a secondary malignancy, with a marked likelihood of the development of other hematologic malignancies including Hodgkin lymphoma and high-grade non-Hodgkin lymphomas. Here, we present the case of two patients who developed diffuse large B cell lymphoma after a long course of hairy cell leukaemia. Read More

View Article and Full-Text PDF

A Rare Case of Good Outcome of Hodgkin Lymphoma in a Patient with HIV on Antiretroviral Therapy (ART).

Am J Case Rep 2022 May 15;23:e936267. Epub 2022 May 15.

Department of Infectious Diseases, Northeast Georgia Medical Center, Gainesville, GA, USA.

BACKGROUND Recent reports have shown an increased incidence of Hodgkin lymphoma (HL) in patients treated with antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection. This report is of a case of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with a good outcome in a 58-year-old Nigerian HIV-positive man who was being treated with ART. CASE REPORT A 58-year-old HIV-positive man presented to a clinic for evaluation of a left axillary mass. Read More

View Article and Full-Text PDF

Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia.

Br J Haematol 2022 May 14. Epub 2022 May 14.

Centre for Lymphoid Cancer and Division of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.

Hodgkin variant Richter transformation (HvRT) is a rare and challenging complication of chronic lymphocytic leukaemia (CLL) for which information on prognostic factors and treatment approaches remain limited. We analysed characteristics and survival outcomes of a population-based cohort of 32 patients with HvRT identified in British Columbia over a 40-year period. Median interval from CLL diagnosis to HvRT was 5. Read More

View Article and Full-Text PDF

New Directions for Mantle Cell Lymphoma in 2022.

Am Soc Clin Oncol Educ Book 2022 Apr;42:1-15

Department of Haematology, Sir Charles Gairdner Hospital, Perth, Australia.

Mantle cell lymphoma is a rare B-cell non-Hodgkin lymphoma that is clinically and biologically heterogeneous. Risk stratification at the time of diagnosis is critical. One of the most powerful prognostic indices is the Mantle Cell Lymphoma International Prognostic Index-Combined, which integrates an estimate of proliferation (Ki67 index) with the standard Mantle Cell Lymphoma International Prognostic Index clinical factors. Read More

View Article and Full-Text PDF

Long-Term Outcomes and Safety Trends of Autologous Stem-Cell Transplantation in Non-Hodgkin Lymphoma: A Report From A Tertiary Care Center in India.

JCO Glob Oncol 2022 May;8:e2100383

Fortis Memorial Research Institute, Gurgaon, India.

Purpose: Published experience with autologous stem-cell transplantation (ASCT) in non-Hodgkin lymphoma (NHL) from the Indian subcontinent is extremely limited. Here, we describe the activity and outcomes of this treatment modality at a large tertiary care center in India.

Patients And Methods: We retrospectively analyzed adult patients with NHL who were eligible for ASCT and autografted between January 1, 2002, and December 15, 2020, at our transplant unit. Read More

View Article and Full-Text PDF

Cancer-Related Psychological Distress in Lymphoma Survivor: An Italian Cross-Sectional Study.

Front Psychol 2022 26;13:872329. Epub 2022 Apr 26.

Unit of Oncological Psychology - Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.

Cancer is becoming a chronic disease, and the number of cancer survivors continues to increase. Lymphoma survivors are also increasing in numbers, and anxiety and depression are among the consequences they face. This study aimed to explore psychological distress in a sample of 212 lymphoma survivors. Read More

View Article and Full-Text PDF

Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma.

Leuk Lymphoma 2022 May 12:1-11. Epub 2022 May 12.

MD Anderson Cancer Center, University of Texas, Houston, TX, USA.

Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma. Combination chemotherapy with immunotherapy can be curative, however, nearly one-third of patients will have a disease that is refractory or will relapse (R/R) after standard first-line therapy. In second-line, the standard treatment strategy for fit patients has been high dose chemotherapy followed by autologous stem cell transplant for a quarter-century, however more than half of patients have chemotherapy-refractory disease with this approach. Read More

View Article and Full-Text PDF

Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis.

J Hematol Oncol 2022 May 11;15(1):57. Epub 2022 May 11.

The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong, Room 407, 4/F, Postgraduate Education Centre, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, NT, Hong Kong SAR, China.

Background: Hodgkin lymphoma is a lymphatic malignancy commonly found in cervical lymph nodes. This study evaluated the worldwide incidence, mortality, associated risk factors, and temporal trends of Hodgkin lymphoma by sex, age, and country.

Methods: The age-standardised Hodgkin lymphoma incidence and mortality were retrieved from the GLOBOCAN, CI5 volumes I-XI, WHO mortality database, the NORDCAN and SEER Program. Read More

View Article and Full-Text PDF

[Oral manifestation of a mantle cell lymphoma - a swelling in the buccal mucosa as the initial manifestation of mantle cell lymphoma: a case report].

Swiss Dent J 2022 May;132(5):343-348

Klinik für Mund-, Kiefer-, Gesichts- und Oralchirurgie, Luzerner Kantonsspital, Luzern, Schweiz.

Lymphomas are malignant neoplasms of mature and immature B-cells, T-cells or NK-cells at various stages of differentiation. They predominantly occur in lymphoid tissues, manifestations in the oral cavity are rare: 3.5% of all oral malignancies are lymphomas. Read More

View Article and Full-Text PDF

Bendamustine treatment of haematological malignancies: significant risks of opportunistic viral, fungal and bacterial infections.

Hematology 2022 Dec;27(1):535-542

Department of Medicine, Queen Mary Hospital, Pokfulam, Hong Kong.

Objectives: Bendamustine is a standard treatment for low-grade B-cell lymphomas, and considered safe in clinical trials. Its safety in routine practice might be different.

Methods: We retrospectively analyzed the infection complications in an unselected cohort of patients treated with bendamustine over a nine-year period. Read More

View Article and Full-Text PDF
December 2022

Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1).

Clin Case Rep 2022 May 5;10(5):e05766. Epub 2022 May 5.

Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation RWTH Aachen University Aachen Germany.

Treatment for Hodgkin lymphoma (HL) in adults comprises substantial risk of chemotherapy-induced peripheral neurotoxicity. Here, we describe the case of patient with Charcot-Marie-Tooth disease or HSMN1 and advanced Hodgkin lymphoma undergoing treatment with modified BEACOPP achieving complete remission without major aggravation of neurological symptoms. Read More

View Article and Full-Text PDF

Impact on the survival of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and monocyte-lymphocyte ratio on prognosis in children with Hodgkin lymphoma.

Saudi Med J 2022 May;43(5):451-457

From the Department of Pediatrics (Ertan, Dogru); and from the Department of Pediatric Hematology and Oncology (Kara, Koksal), Faculty of Medicine, Selcuk University, Konya, Turkey.

Objectives: To evaluate the clinical utility of the recently described absolute neutrophil counts to absolute lymphocyte counts ratio (NLR), absolute platelet counts to absolute lymphocyte counts ratio (PLR), and absolute monocyte counts to absolute lymphocyte counts ratio (MLR) on prognosis in children with Hodgkin lymphoma (HL).

Methods: We retrospectively evaluated the clinical characteristics, laboratory features (lymphocyte counts, NLR, PLR, and MLR), treatment, and results of 52 children with HL in the Department of Pediatric Hematology and Oncology, Selcuk University, konya, Turkey, from January 2006 until December 2021.

Results: The patients included 27 (51. Read More

View Article and Full-Text PDF